4.7 Review

Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models

期刊

出版社

MDPI
DOI: 10.3390/ijms23105634

关键词

SGLT2i; inflammation; M1; M2 macrophages; NLRP3 inflammasome; pyroptosis; metaflammation; cytokines

资金

  1. National Institute of Health Fondo de Investigaciones Sanitarias del Instituto de Salud Carlos III Madrid, Spain [PI21/01145, RD16/0012/0014]
  2. European Regional Development Fund (FEDER)
  3. European Union [734899]
  4. Axencia Galega de Innovacion (GAIN): Axudas do programa de consolidacion e estruturacion de unidades de investigacion competitivas [GPC IN607B 2021 108]
  5. Xunta de Galicia
  6. Spanish Ministry of Science
  7. Instituto de Salud Carlos III (Spain)
  8. National Institute of Health Fondo de Investigaciones Sanitarias del Instituto de Salud Carlos III Madrid, Spain [CIBER de Enfermedades Cardiovasculares (CIBERCV)]

向作者/读者索取更多资源

Sodium-glucose co-transporter 2 inhibitors, known as gliflozins, not only regulate glucose homeostasis and show cardio-renal protective effects in patients with heart failure, but also have anti-inflammatory properties, which may be beneficial for treating other diseases associated with inflammation.
Sodium-glucose co-transporter 2 inhibitors, also known as gliflozins, were developed as a novel class of anti-diabetic agents that promote glycosuria through the prevention of glucose reabsorption in the proximal tubule by sodium-glucose co-transporter 2. Beyond the regulation of glucose homeostasis, they resulted as being effective in different clinical trials in patients with heart failure, showing a strong cardio-renal protective effect in diabetic, but also in non-diabetic patients, which highlights the possible existence of other mechanisms through which gliflozins could be exerting their action. So far, different gliflozins have been approved for their therapeutic use in T2DM, heart failure, and diabetic kidney disease in different countries, all of them being diseases that have in common a deregulation of the inflammatory process associated with the pathology, which perpetuates and worsens the disease. This inflammatory deregulation has been observed in many other diseases, which led the scientific community to have a growing interest in the understanding of the biological processes that lead to or control inflammation deregulation in order to be able to identify potential therapeutic targets that could revert this situation and contribute to the amelioration of the disease. In this line, recent studies showed that gliflozins also act as an anti-inflammatory drug, and have been proposed as a useful strategy to treat other diseases linked to inflammation in addition to cardio-renal diseases, such as diabetes, obesity, atherosclerosis, or non-alcoholic fatty liver disease. In this work, we will review recent studies regarding the role of the main sodium-glucose co-transporter 2 inhibitors in the control of inflammation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据